Evidence map›Paper›PMID 24711694›Full record

ReviewDrug design, development and therapy2014

Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis.

Francesco Semeraro, Barbara Arcidiacono, Giuseppe Nascimbeni, Martina Angi, Barbara Parolini, Ciro Costagliola

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Francesco SemeraroEye Clinic, Department of Neurological Sciences and Vision, University of Brescia, Brescia, Italy.
Barbara ArcidiaconoDepartment of Ophthalmology, S. Anna Hospital, Brescia, Italy.
Giuseppe NascimbeniEye Clinic, Department of Neurological Sciences and Vision, University of Brescia, Brescia, Italy.
Martina AngiEye Clinic, Department of Neurological Sciences and Vision, University of Brescia, Brescia, Italy.
Barbara ParoliniDepartment of Ophthalmology, S. Anna Hospital, Brescia, Italy.
Ciro CostagliolaEye Clinic, Department of Health Sciences, University of Molise, Campobasso, Italy.
University of Brescia · ITUniversity of Molise · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Juvenile idiopathic arthritis-related uveitis is the most common type of uveitis in childhood and one of the main causes of visual impairment in children. The introduction of biological treatment has widened the range of therapeutic options for children with uveitis refractory to standard nonbiologic immunosuppressants. Data from clinical trials suggest that both adalimumab and infliximab have demonstrated effectiveness and safety in open-label studies, although no large, randomized, controlled trials have been reported so far. The role of etanercept in treating juvenile idiopathic arthritis-related uveitis is not yet well defined. In our experience, anti-tumor necrosis factor therapy has been shown to be more effective than steroids and/or methotrexate in treating uveitis. Up to now, tumor necrosis factor blocking compounds have been reserved for the treatment of the most severe cases of refractory uveitis, and larger prospective clinical trials are required in order to better assess the safety of these new compounds.

Indexed as

AdalimumabAdolescentAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, JuvenileEtanerceptHumansImmunoglobulin GInfliximabReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alphaUveitisAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedEtanerceptgolimumabImmunoglobulin GInfliximabReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alphaadalimumabetanerceptinfliximab

Identifiers

PMID24711694
PMCPMC3969254
OpenAlexW1993198644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.